Dual Use Therapeutics for Cryptosporidiosis, Toxoplasmosis, and Neosporosis

隐孢子虫病、弓形虫病和新孢子虫病的双重用途疗法

基本信息

批准号：
9102210
负责人：
WESLEY C VAN VOORHIS
金额：
$ 33.89万
依托单位：
UNIVERSITY OF WASHINGTON
依托单位国家：
美国
项目类别：
财政年份：
2014
资助国家：
美国
起止时间：
2014-09-24 至 2019-06-30
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/9102210
关键词：
2 year old Animal Diseases Animal Model Animals Binding Sites Blood Cattle Cell Culture Techniques Cell Proliferation Chemicals Child Childhood Clinical Congenital Abnormality Cryptosporidiosis Cryptosporidium Cryptosporidium parvum Diarrhea Digit structure Domestic Animals Dose Drug Design Drug Kinetics Drug Packaging Economics Epidemic Excretory function Feces Fetus Funding Gatekeeping Glycine Goals Goat Health Human Immunocompromised Host Industry Infection Kilogram Lead Link Livestock Mammalian Cell Metabolism Milk Modeling Mus National Institute of Allergy and Infectious Disease Neospora caninum Newborn Infant Pharmaceutical Preparations Phosphotransferases Preclinical Testing Pregnant Women Primary Infection Property Protein Kinase Relapse Rodent Model Ruminants Sampling Sheep Structure Testing Therapeutic Therapeutic Uses Time Tissues Toxic effect Toxicity Tests Toxicology Toxoplasma gondii Toxoplasmosis abortion absorption base calcium-dependent protein kinase drug candidate drug development drug metabolism efficacy testing fetal in vivo information gathering kinase inhibitor malformation meetings mortality mouse model novel therapeutics pre-clinical preclinical study pregnant prevent scale up wasting

项目摘要

DESCRIPTION (provided by applicant): New drugs are urgently needed for cryptosporidiosis and toxoplasmosis for human and domestic livestock use. Cryptosporidiosis causes wasting diarrhea in humans and calves. Toxoplasmosis is an important cause of fetal malformations and abortions in humans and domestic livestock. In addition, an effective drug is also needed for veterinary use for neosporosis, the cause of epidemic abortions in livestock. This project follows on our successful hit-to-lead drug development project, targeting protozoan Calcium Dependent Protein Kinases (CDPKs). We now have two promising pre-clinical drug candidates that show activity in mouse models of cryptosporidiosis, toxoplasmosis and neosporosis, and thus are of great potential value for both veterinary and human health. The goal of this project will be to conduct efficacy, pharmacokinetic (PK), and toxicity testing of our novel therapeutics in agriculturally-important domestic animals (cattle and sheep) to show efficacy for animal diseases and to also gather information for the preclinical drug package for human use. We will scale-up the compounds to the near kilogram quantity, test their efficacy in sheep models of toxoplasmosis and neosporosis, and in a calf model of cryptosporidiosis. In the end of this project, the goal is to have a preclinical drug candidate and one or two backups to advance to final preclinical testing and IND/NADA registration for veterinary and human use.

描述（由申请人提供）：迫切需要新药才能用于使用人和家庭牲畜的隐孢子虫病和弓形虫病。隐孢子虫病会导致人类和小牛浪费腹泻。弓形虫病是人类和家庭牲畜胎儿畸形和堕胎的重要原因。此外，还需要一种有效的药物来用于新的孢子症，这是牲畜流行流产的原因。该项目遵循我们成功的命中率到铅的药物开发项目，以原生动物钙依赖性蛋白激酶（CDPK）为目标。现在，我们有两个有希望的临床前药物候选物，它们在隐孢子虫病，弓形虫病和新孢子中症的小鼠模型中显示活性，因此对于兽医和人类健康都是巨大的潜在价值。该项目的目的是进行疗效，药代动力学（PK）和我们对农业重要的家畜（牛和绵羊）的新型治疗学对动物疾病的疗效，并收集有关人类使用的长状药物包装的信息。我们将将化合物扩大到接近千克的数量，测试其在弓形虫病和新孢子虫病的绵羊模型中的功效，以及在隐孢子虫病的小腿模型中。在该项目的最后，目标是要有一个临床前药物和一两个备份，以促进最终的临床前测试和IND/NADA注册，以供兽医和人类使用。